Literature DB >> 226640

Determination of mevalonate in blood plasma in man and rat. Mevalonate "tolerance" tests in man.

G Popják, G Boehm, T S Parker, J Edmond, P A Edwards, A M Fogelman.   

Abstract

A method is described for the determination of mevalonate in ultrafiltrates of blood plasma. The method depends on the phosphorylation of mevalonate with [gamma-32P]ATP and mevalonate kinase to 5-[32P]phosphomevalonate, and the subsequent isolation of the 5-[32P]phosphomevalonate together with known amounts of added 5-phospho[14C]mevalonate by ion-exchange chromatography. The 32P/14C ratio in the isolated 5-phosphomevalonate is a linear function of the mevalonate content of the samples. The smallest amount that can be determined is 1--2 pmol. The fasting level in human plasma varied between 20 and 75 pmol/ml. Human red blood cells absorb mevalonate from plasma relatively slowly; their maximum storage capacity is about 1.3 pmol/10(6) red cells. An oral and intravenous "mevalonate tolerance test" in man is described that can be carried out with 200 and 30 mumol. respectively, of the unlabeled (RS)-mevalonate in a 70-kg man. Beer and wine contain mevalonate at a concentration of 3--8 microns, too low to provide a significant amount of mevalonate even for heavy drinkers. The mevalonate content of the plasma from the blood of the vena cava inferior of male rats varied between 81 and 502 pmol/ml and is positively related to the levels of liver 3-hydroxy-3-methylgultaryl-CoA reductase, suggesting that the liver is probably the main source of mevalonate circulating in blood. The plasma of renal venous blood contained only 33--85% as much mevalonate as the arterial plasma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 226640

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  21 in total

1.  A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine.

Authors:  S G Young; C M Cham; R E Pitas; B J Burri; A Connolly; L Flynn; A S Pappu; J S Wong; R L Hamilton; R V Farese
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

2.  Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.

Authors:  T Yoshida; A Honda; J Shoda; M Abei; Y Matsuzaki; N Tanaka; H Miyazaki; T Osuga
Journal:  Lipids       Date:  1997-08       Impact factor: 1.880

3.  The effect of diabetes on mevalonate metabolism in the rat.

Authors:  M H Wiley; K R Feingold; M M Howton; M D Siperstein
Journal:  Diabetologia       Date:  1982-02       Impact factor: 10.122

4.  Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man.

Authors:  T S Parker; D J McNamara; C Brown; O Garrigan; R Kolb; H Batwin; E H Ahrens
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

5.  Role of the kidneys in the metabolism of plasma mevalonate. Studies in humans and in rhesus monkeys.

Authors:  D J McNamara; E H Ahrens; T S Parker; K Morrissey
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

6.  Diurnal variation of plasma methyl sterols and cholesterol in the rat: relation to hepatic cholesterol synthesis.

Authors:  T E Strandberg; R S Tilvis; T A Miettinen
Journal:  Lipids       Date:  1984-03       Impact factor: 1.880

7.  (R)-mevalonate excretion in human and rat urines.

Authors:  R R Kopito; H Brunengraber
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

8.  Sex difference in human mevalonate metabolism.

Authors:  K R Feingold; M H Wiley; G L Searle; B K Machida; M D Siperstein
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

9.  Plasma mevalonate as a measure of cholesterol synthesis in man.

Authors:  T S Parker; D J McNamara; C D Brown; R Kolb; E H Ahrens; A W Alberts; J Tobert; J Chen; P J De Schepper
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

10.  Determination of key intermediates in cholesterol and bile acid biosynthesis by stable isotope dilution mass spectrometry.

Authors:  Tadashi Yoshida; Akira Honda; Hiroshi Miyazaki; Yasushi Matsuzaki
Journal:  Anal Chem Insights       Date:  2008-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.